

A Phase II Study of Antineoplastons A10 and AS2-1 in Children with Recurrent, Refractory or Progressive Primary Brain Tumors—Final Report (Protocol BT-22)

Stanislaw R. Burzynski, Tomasz J. Janicki, Gregory S. Burzynski, Ania Marszalek, Sheldon Brookman

Burzynski Clinic, Houston, Texas, USA

Email: gbs@burzynskclinic.com

Received 13 July 2014; revised 8 August 2014; accepted 3 September 2014

Copyright © 2014 by authors and Scientific Research Publishing Inc.

This work is licensed under the Creative Commons Attribution International License (CC BY).

<http://creativecommons.org/licenses/by/4.0/>



Open Access

Abstract

Primary malignant brain tumors are a leading cause of cancer-related death in children. This Phase II study evaluated the efficacy and safety of Antineoplastons A10 and AS2-1 (ANP) in children who developed progression during standard treatment. A total of 43 children were recruited to the study, but only 41 met eligibility criteria. There were twelve cases of glioblastoma multiforme (GBM), eight anaplastic astrocytomas (AA), twelve diffuse intrinsic pontine gliomas (DIPG), three supertentorial primitive neuroectodermal tumors (sPNET), three cases of medulloblastoma and one case each of anaplastic ependymoma (AE), atypical teratoid rhabdoid tumor (AT/RT), and disseminated pilocytic astrocytoma (PAD). ANP was administered intravenously daily every four hours (median dose of A10 8.74 g/kg/d and AS2-1 0.35 g/kg/d), until objective response (OR) was documented, and then a further eight months. All enrolled patients were included in safety, but only eligible patients in the efficacy evaluation. A total of 12.2% of patients obtained OR; 2.4% complete response (CR) and 9.8% partial response (PR). Stable disease (SD) was determined in 17.1% and progressive disease (PD) in 43.9% of cases. There were 26.8% of nonevaluable (NE) cases due to premature discontinuation. Out of five OR cases, four patients were diagnosed with recurrent DIPG and one with recurrent AA. Median progression-free survival (PFS) was 2.5 months. Median overall survival was 4.8 months. OS at 6 months was 46.3%, one year was 12.2%, and 4.8% at two, five, and ten years. The longest survivor is a patient diagnosed with DIPG and gliosarcoma who remains alive more than 15 years. A group of eleven patients reported grade 3 and 4 toxicity including hypernatremia in eight cases, somnolence in two cases, and hypokalemia in one case. There were no chronic toxicities, and the quality of life was very good. The largest group of patients were represented by DIPG, GBM, and AA. The best results were obtained in the DIPG and AA groups. In the DIPG group, CR was in 8.3%, PR was 25%, median PFS was 4.8 months,

How to cite this paper: Burzynski, S.R., Janicki, T.J., Burzynski, G.S., Marszalek, A. and Brookman, S. (2014) A Phase II Study of Antineoplastons A10 and AS2-1 in Children with Recurrent, Refractory or Progressive Primary Brain Tumors—Final Report (Protocol BT-22). *Journal of Cancer Therapy*, 5, 977-988. <http://dx.doi.org/10.4236/jct.2014.510102>

median OS was 6.1 months, and OS at 6 months was 58.3%, at one year 25%, and 8.3% at two, five, and ten years. In the AA group, PR was 12.5%, median PFS was 3.7 months, median OS was 4.7 months, and OS at 6 months was 37.5%, and 12.5%, at one, two, five, and ten years. In conclusion, antineoplastons showed efficacy and acceptable toxicity in patients with recurrent, refractory or progressive primary brain tumors.

Keywords

Anaplastic Astrocytoma, Antineoplastons A10 and AS2-1, Brainstem Glioma, Diffuse Intrinsic Pontine Glioma (DIPG), Gliosarcoma, Phase II Clinical Trial, Recurrent Glioma

1. Introduction

Pediatric primary malignant brain tumors are a leading cause of cancer-related deaths in children [1]. Pediatric high-grade gliomas (HGG) are relatively uncommon and represent approximately 17% of all pediatric brain tumors [2]. Supratentorial HGG and diffuse intrinsic pontine glioma (DIPG) continue to be two main challenges for pediatric oncologists [3]. The standard of care for newly diagnosed HGG is surgical resection followed with daily temozolomide (TMZ) and radiation therapy (RT) with subsequent adjuvant TMZ [4] [5]. Standard RT continues to be the main treatment for newly diagnosed DIPG. Unfortunately, there are no standard therapy recommendations after recurrence [5]-[7].

Antineoplastons A10 and AS2-1 (ANP) have been tested extensively in Phase II studies in primary brain tumors. Initial clinical responses in the treatment of HGG and DIPG convinced us to design and conduct a single-arm Phase II study of ANP therapy to assess the efficacy and safety in children diagnosed with primary malignant brain tumors, mostly gliomas, which failed to respond to standard therapy [8]-[12].

2. Patients and Methods

2.1. Patient Population

Recruited patients were between 6 months old and 18 years with radiologic evidence of recurrent, refractory, progressive or persistent primary brain tumors after receiving standard therapy, by gadolinium-enhanced magnetic resonance imaging (MRI) performed within 14 days prior to initiating the study. Patients were required to have a histologically confirmed, incurable primary malignant brain tumor or DIPG, and to have a complete recovery and at least four weeks from prior surgical procedure. At least eight weeks must have elapsed since the last dose of RT, and at least four weeks must have elapsed since the last dose of chemotherapy (six weeks for nitrosoureas) or immunotherapy. However, patients with clear evidence of disease progression during the initial therapy could be enrolled less than 8 weeks following the last dose of RT, less than 4 weeks after surgery or the last dose of chemotherapy, if the investigator determined that it was safe to administer ANP to such patients.

Diagnosis made by MRI without the necessity of a biopsy is generally accepted for brainstem glioma (BSG). Based on MRI alone, DIPG could be diagnosed if the tumor has an epicenter in the pons and involved more than 50% of the pons. Patients with tumors that involved the thalamus or upper cervical regions of the spinal cord were also classified as DIPG if the lesion primarily involved the brainstem. Patients with neurofibromatosis were not covered by this definition and were not included. Tumors involving less than 50% of the pons or exophytic or exophytic involving from pons were classified as DIPG if they had anaplastic, glioblastoma (GBM) or gliosarcoma (GS) histology [6] [13]-[15]. The remaining types of BSG included focal, exophytic, cervicomedullary, and midbrain tumors [16] [17].

Patients were required to have a gadolinium-enhanced MRI performed within two weeks prior to study enrollment. There were no exclusion criteria based on tumor size, multifocality or leptomeningeal or the presence of systemic metastases. Eligibility criteria also included a Karnofsky Performance Status (KPS) of 60 - 100. A group of patients admitted, based on Special Exceptions permitted by the Food and Drug Administration (FDA), had a KPS below 60. The subjects were required to have relatively normal hematopoietic and hepatic function with white blood cell count (WBC) over 1500/mm³ and platelet count over 50,000/mm³, no evidence of hepatic

or renal insufficiency, and a total bilirubin and serum creatinine of no higher than 2.5 mg/dL and SGOT and SGPT no higher than 5× the upper limits. Use of corticosteroids was permitted to reduce symptoms and signs attributed to cerebral edema, but it was recommended that the smallest doses compatible with the preservation of optimal neurologic function be used. Confirmation of the pathologic diagnosis by an outside pathologist was also required.

The exclusion criteria included serious active infection, fever or other serious concomitant disease that would interfere with the evaluation of the treatment (e.g., severe heart or lung disease). Criteria for the removal from the study were the same as in studies BT-06 and BT-11, and were described previously [10] [12].

All study subjects and/or guardians read, understood, and signed written informed consents prior to enrollment. This study was conducted in accordance with the US Code of Federal Regulations, Title 21, Parts 11, 50, 56, and 312; the Declaration of Helsinki (1964) including all amendments and revisions; the Good Clinical Practices: Consolidated Guideline (E6); International Conference on Harmonization; and the FDA Guidance for Industry. The study was sponsored by the Burzynski Research Institute, Inc., (BRI) and conducted by the Burzynski Clinic (BC) in Houston, Texas.

2.2. Study Design

The study was a single-arm, two-stage, interventional Phase II trial of ANP as the monotherapy in a high-risk, poor-prognosis study population. The study was listed by the National Cancer Institute (NCI) under the number of NCT00003476. The study was overseen by an independent Institutional Review Board.

The study was performed according to Protocol BT-22 and conducted under the U.S. IND 43,742. The study commenced on March 6, 1996 and was closed to accrual on November 15, 2011. The protocol was amended by BRI several times; however, none of the amendments altered the aim or design of the original study objectives.

3. Statistical Consideration

The sample size and statistical methods were based upon the method described by Chang *et al.* and were described before [18]. A response rate to ANP of $\geq 10\%$ was considered 'of interest,' and the primary endpoint was to determine the overall response rate (confirmed complete response (CR) or partial response (PR)) to ANP therapy. An interim analysis would be conducted after 20 subjects had enrolled in the study. If one or more patients achieved a confirmed radiographic response, an additional 20 subjects would be recruited. Overall survival (OS) was measured from the first day of ANP administration until death from any cause, and progression-free survival (PFS) was measured from the first day of the treatment until the date of first observation of progressive disease (PD), beginning of other treatment or death. OS and PFS were estimated by Kaplan-Meier analysis using the MedCalc Statistical Software version 13.3 (MedCalc Software bvba, Ostend, Belgium; 2014). The primary endpoint was the response to treatment which was determined in these different populations: 1) study eligible, 2) DIPG, and 3) anaplastic astrocytoma (AA). Time to best response, dosage, and duration of treatment were analyzed. The average maximum effective daily dose and the range were calculated.

4. Treatment Plan

ANPs A10 and AS2-1 were delivered via a dual-channel infusion pump and a single-lumen subclavian catheter (Broviac, Groshong or Hickman) every 4 hours as described before [10] [12]. Criteria for using additional medications including corticosteroids and for outpatient treatment and monitoring were previously described [10] [12].

5. Evaluation and Follow-Up

Tumor measurements were based on contrast-enhanced lesions identified by MRI, T2 and FLAIR images were also evaluated [10] [15] [19]. Blood and urine tests and additional measurements were performed as previously described [10] [12]. MRIs were repeated at least every 8 weeks during the first 2 years unless the patient's condition or confirmation of response required an MRI within 4 weeks. Positron emission tomography (PET) scans were performed as necessary. The adverse events were evaluated in all patients and graded according to the Common Terminology Criteria for Adverse Events v. 3 (CTCAE v.3).

6. Results

6.1. Patient Demographic

Subject enrollment started March 6, 1996 and continued through November 15, 2011. As of May 15, 2013, all subjects were removed from the therapy due to a CR, PR, subject request, PD, or worsening clinical condition. The results were analyzed in a group of 43 patients from which only 41 were eligible for efficacy. Two patients with AA were found ineligible; none of them received prior treatment. The response of both patients was classified as stable disease (SD). The largest groups were patients with DIPG, GBM, and AA. The best results were obtained in the DIPG and AA groups. The characteristic of the eligible patients are summarized in **Table 1**.

Table 1. Patient characteristics.

Characteristic	Number
Age (range years)	1.4 - 18.5
Male	20
Female	21
Race	
White	36
African-American	1
Latin American	3
Oriental	1
Prior therapy	
Surgery and chemotherapy	3
Surgery and radiation	3
Chemotherapy only	1
Radiation only	5
Chemotherapy and radiation	5
Surgery, chemotherapy, and radiation	16
Surgery, chemotherapy, radiation and ABMT/SCR	4
Surgery, radiation and targeted/biological therapy	2
Surgery, radiation, chemotherapy and targeted/biological therapy	1
Radiation and targeted/biological therapy	1
Diagnosis	
DIPG	12
GBM	12
AA	8
Medulloblastoma	3
sPNET	3
AE	1
AT/RT	1
PAD	1
Karnofsky performance score	
Median	50
Range	40-90

Abbreviations: AA—anaplastic astrocytoma; AE—anaplastic ependymoma; AT/RT—atypical teratoid rhabdoid tumor; ABMT—autologous bone marrow transplant; DIPG—diffuse intrinsic brainstem glioma; GBM—glioblastoma multiforme; PAD—disseminated pilocytic astrocytoma; SCR—stem cell rescue; sPNET—supratentorial primitive neuroectodermal tumor.

Among 41 eligible patients, there were 12 cases of GBM, 8 anaplastic astrocytoma (AA), 12 DIPG, 3 medulloblastoma, 3 supratentorial primitive neuroectodermal tumor (sPNET), and 1 each of anaplastic ependymoma (AE), atypical teratoid rhabdoid tumor (AT/RT), and disseminated pilocytic astrocytoma (PAD). Recurrent tumors among patients with objective response (OR) and SD were diagnosed in 92%, and persistent tumors in 8%.

6.2. Treatment

The median daily doses of ANP A10 and AS2-1 are described in [Table 2](#).

The median time to first OR was 19 weeks (range 7 to 38 weeks). The duration of IV ANP therapy ranged from 0.4 to 77 weeks with a median of 13.7 weeks. One subject had a CR and therapy ended after 59 weeks of IV treatment. Six patients halted the treatment based on their decision. Eight subjects halted therapy due to PD confirmed by MRI. In 26 cases, ANP were stopped due to worsening of their clinical condition and 6 patients died while on treatment from the underlying disease.

7. Responses and Survival

The data on confirmation of diagnosis, recurrence and response among OR and SD patients are shown in [Table 3](#).

[Table 4](#) shows the response rate and survival for study eligible population as well as for subgroups.

A total of five patients (12.2%) obtained OR to ANP—one case of CR (2.4%) and four cases of PR (9.8%). A patient diagnosed with DIPG and disseminated GS achieved a CR, and is now surviving over 15 years since treatment start ([Figure 1](#)) [11].

SD was determined in 7 cases (17.1%) and PD in 18 cases (43.9%). There were 11 NE cases (26.8%) due to premature discontinuation of treatment based on the patient's decision in 3 cases, and deterioration of patients' condition in 8 cases, 2 patients from this group died due to underlying malignancy while on treatment. In the eligible study group, OS was 46.3% at 6 months, 12.2% at one year and 4.8% at two, five and ten years. The PFS at six months was 22%. In the DIPG group, OS was 58.3% at 6 months, 25.0% at one year and 8.3% at two, five and ten years. The PFS at six months was 41.7%. In the AA group, OS was 37.5% at 6 months, 12.5% at one, two, five and ten years. The PFS at six months was 25.0%. The Kaplan-Meier overall survival and progression-free survival curves for all patient cases are presented in [Figure 2](#) and [Figure 3](#). Detailed descriptions of some successfully treated cases have been presented in interim reports [8] [11].

The comparison of the results of treatment with ANP versus temozolomide in recurrent or progressive brain tumors in children are shown in [Table 5](#).

Table 2. Median daily dose of ANP A10 and AS2-1.

		Median daily dose g/kg/d (Range)					
		Entire treatment		Dose until documented OR achieved		Dose until documented SD achieved	
Treated patients	N	A10	AS2-1	A10	AS2-1	A10	AS2-1
All	41	8.74 (0.48 - 24.58)	0.35 (0.13 - 0.51)	10.58 (9.46 - 16.89)	0.35 (0.32 - 0.44)	9.23 (6.75 - 24.58)	0.39 (0.27 - 0.47)
DIPG	12	10.26 (1.85 - 24.58)	0.37 (0.27 - 0.51)	11.46 (9.46 - 16.89)	0.40 (0.34 - 0.44)	8.65 (6.75 - 24.58)	0.41 (0.27 - 0.47)
AA	8	6.29 (1.93 - 13.09)	0.30 (0.22 - 0.44)	9.87*	0.32*	7.88*	0.29*
GBM	12	8.47 (1.61 - 13.38)	0.33 (0.13 - 0.46)	—	—	12.04 (10.72 - 13.36)	0.40 (0.39 - 0.40)

*Only one patient. Abbreviations: AA—anaplastic astrocytoma; DIPG—diffuse intrinsic pontine glioma; GBM—glioblastoma multiforme; OR—objective response; SD—stable disease.

Table 3. Confirmation of diagnosis, recurrence and response.

Patient	Confirmation of diagnosis					Prior treatment	Confirmation of recurrence		Confirmation of response to ANP		Tumor measurements		
	Pathology		Radiology				Date	Assessment	Place and date	Assessment	MRI		PET
	Place and date	Diagnosis	Place and date	Diagnosis	Enhancing						Non-enhancing		
1	AMC, March 10, 1995 February 26, 1999	A GS	AMC, March 24, 1999	DIPG	2S 3RT 2C HDC	December 3, 1999	Recurrent tumor, DIPG and multicentric	External radiology, CRR, April 12, 2000	CR	Decreased over 50%	Decreased	Resolved	
2			AMC, August 9, 1999	DIPG	RT	November 3, 1999	Recurrent tumor	External radiology, CRR February 23, 2000	PR	Decreased over 50%	Decreased		
3			AMC, January 4, 1999	DIPG	RT C	April 27, 1999	Recurrent tumor	External radiology, CRR June 18, 1999	PR	Decreased over 50%	Decreased		
4			AMC, April 11, 2011	DIPG	RT C Targeted (bevacizumab)	October 20, 2011	Recurrent tumor	External radiology, July 30, 2012	PR	Decreased over 50%	Decreased		
5			RG, December 3, 1995	DIPG	RT	February 21, 1996	Recurrent tumor	External radiology, May 22, 1996	SD	Stable	Stable		
6			AMC, July 31, 1998	DIPG	RT	October 26, 1998	Recurrent tumor	External radiology, March 18, 1999	SD	Stable	Stable		
7	AMC, March 30, 2005	A2	RG, March 10, 2005	DIPG	C	May 24, 2005	Recurrent tumor	External radiology, September 12, 2005	SD	Stable	Stable		
8			RG, March 1, 2010	DIPG	RT C	July 27, 2010	Persistent tumor	RG, May 26, 2011	SD	Stable	Stable		
9	AMC, August 24, 1999	AA	AMC, August 20, 1999	Right thalamic tumor	RT	October 27, 1999	Recurrent tumor	External radiology, CRR, April 12, 2000	PR	Decreased over 50%	Stable		
10	AMC, December 24, 1998	AA	AMC, December 19, 1997	Left temporal tumor	2S RT 4C	September 23, 1999	Recurrent tumor	External radiology, June 18, 2000	SD	Stable	Stable		
11	AMC, May 19, 2003	GBM	AMC, May 12, 2003	Left temporal tumor	S RT C	August 20, 2003	Recurrent tumor	External radiology, December 4, 2003	SD	Stable	Decreased		
12	AMC, May 8, 2009	GBM	AMC, June 2, 2009	Right temporal tumor	2S RT 2C	October 14, 2009	Recurrent tumor	External radiology, February 8, 2010	SD	Stable	Stable		

*This table includes patients whose responses were determined as CR, PR and SD only, which are of main interest to the readers. Radiology diagnosis is different than pathology diagnosis because the radiology diagnosis is based on the location of the tumor in the brain and the pathology diagnosis is based on the microscopic appearance. Abbreviations: A—astrocytoma; A2—astrocytoma, grade 2; AA—anaplastic astrocytoma; AMC—academic medical center; C—chemotherapy; CR—complete response; CRR—central radiology review; DIPG—diffuse intrinsic pontine glioma; GBM—glioblastoma multiforme; GS—gliosarcoma; HDC—high-dose chemotherapy; PR—partial response; RG—regional hospital; RT—radiation therapy; S—surgery; SD—stable disease.

8. Safety and Adverse Events

Study Population

Safety assessments were analyzed based upon the total number of enrolled patients in the study ($n = 43$). Intense monitoring of patient safety was conducted during the first two months of therapy and involved daily direct




Figure 1. Patient 1. (A) Baseline MRI; (B) Follow-up MRI indicating PR. Coronal T-1 contrast-enhanced images. A CR was confirmed by PET scan.




Figure 2. The Kaplan-Meier survival curve. Overall survival from the treatment start.




Figure 3. The Kaplan-Meier survival curve. Progression-free survival from the treatment start.

Table 4. Response rates and overall survival.

Diagnosis	N	Response N (%)					Survival Median (range) in months
		CR	PR	SD	PD	NE	
DIPG	12	1	3	4	2	2	6.1 (0.5 - 173.5+)
GBM	12			2	8	2	4.4 (0.5 - 11.1)
AA	8		1	1	3	3	4.7 (1.1 - 136.7)
Medulloblastoma	3					3	0.9 (0.5 - 0.9)
sPNET	3				3		3.4 (3.3 - 8.5)
PAD	1				1		19.8
AE	1					1	10.5
AT/RT	1				1		3.2
TOTAL	41	1 (2.4)	4 (9.8)	7 (17.1)	18 (43.9)	11 (26.8)	4.8 (0.5 - 173.5+)

Abbreviations: AA—*anaplastic astrocytoma*; AE—*anaplastic ependymoma*; AT/RT—*atypical teratoid rhabdoid tumor*; CR—*complete response*; DIPG—*diffuse intrinsic brainstem glioma*; GBM—*glioblastoma multiforme*; NE—*non-evaluable*; PAD—*disseminated pilocytic astrocytoma*; PD—*progressive disease*; PR—*partial response*; SD—*stable disease*; sPNET—*supratentorial primitive neuroectodermal tumor*. +Patient alive.

questioning concerning adverse events, initially at the clinic and then followed by daily phone calls during the home administration phase. After two months, telephone contact was conducted on at least a weekly basis. Adverse events were coded and graded according to CTCAE v.3. No long-term adverse drug events (ADEs) to ANPs were reported.

ADEs grades 3 and 4 identified and reported by study patients in comparison to other studies is shown in **Table 6**.

Brain tumor patients frequently receive corticosteroids as part of their therapeutic regimen to reduce cerebral edema around tumors. The use of corticosteroids, the infusion of large volumes of sodium-containing solutions during ANP therapy, and the brain tumor itself predispose a patient to an increased incidence of serum sodium concentration abnormalities. As a result, grade 3 reversible hyponatremia was reported in two cases and grade 4 hyponatremia was reported in six cases (4.6% and 13.9% respectively). In the studies with temozolomide, there was substantial myelotoxicity, vomiting, and incidence of infection including sepsis and pneumonia reported in **Table 6**.

Table 5. Phase II clinical studies in recurrent or progressive brain tumors in children. The results of chemotherapy with temozolomide vs. antineoplastons.

Reference/ treatment	Patients		Prior treatment	Efficacy response %			Survival analysis								
	Total No.	Radiation therapy %		Chemotherapy %	CR	PR	SD	PFS (%)		OS (%)					
			Median-months					6 months	Median-months	6 months	1 year	2 years	5 years	10 years	
Lashford <i>et al.</i> , 2002, Temozolomide [21]	43	All	63	0	9	14			4.8						
Nicholson <i>et al.</i> , 2007, Temozolomide [22]	23	84	All	0	4	30									
Warren <i>et al.</i> , 2012, 06-benzylguanine and temozolomide [23]	41	All	1 median chemo therapy regimen	0	2	12		16* 0**							
Burzynski <i>et al.</i> , 2014, ANP(Study eligible)	41	90.2	80.5	2.4	9.8	17.1	2.5	22	4.8	46.3	12.2	4.8	4.8	4.8	
Burzynski <i>et al.</i> , 2014, ANP (DIPG)	12	91.6	75.0	8.3	25	33.3	4.8	41.7	6.1	58.3	25.0	8.3	8.3	8.5	
Burzynski <i>et al.</i> , 2014, ANP (AA)	8	87.5	75	0	12.5	12.5	3.7	25.0	4.7	37.5	12.5	12.5	12.5	12.5	

Abbreviations: AA—anaplastic astrocytoma; ANP—antineoplastons A10 and AS2-1; CR—complete response; DIPG—diffuse intrinsic pontine glioma; HGG—high grade glioma; OS—overall survival; PFS—progression-free survival; PR—partial response; SD—stable disease; *Stratum A, HGG; **Stratum B, DIPG.

9. Discussion

The breakthrough in molecular and genomic studies brought justified excitement into the research on primary malignant brain tumors [20]. Until these new data are translated into clinical results it is necessary to rely on currently available treatment modalities which do not prove the efficacy beyond standard RT, which remains the accepted treatment for newly-diagnosed HGG and DIPG. Clinical trials in pediatric HGG and DIPG were extensively reviewed previously [6] [7] [9]. Recently, seven trials were conducted for a mixed population of pediatric patients, usually for HGG with a percentage of patients diagnosed with DIPG. These studies were reviewed by us in recent publications [10] [12]. Lashford *et al.*, Nicholson *et al.* and Warren *et al.* reported on studies with temozolomide in the treatment of children diagnosed with HGG and DIPG [21]-[23]. In these studies, 23 to 43 children who failed radiation therapy and chemotherapy were recruited. No CRs in their studies were accomplished, but they reported from 2% to 9% for PR and 14% to 30% for SD. Limited survival data were reported. There were no median PFSs determined and 6 months PFS in the Warren *et al.* study was 16% for HGG and 0% for DIPG [23]. OS was only reported by Lashford *et al.* as 4.8 months median survival (Table 5).

The results of our clinical trials indicate a significant percentage of CR and PR in a small group of recurrent DIPG (4 out of 12 patients). In the recurrent AA group of eight patients, there were single cases of PR and SD. It should be emphasized that the study accrued a very difficult-to-treat population compared to other ANP studies provided rationale for future Phase III studies.

Table 6. Incidence of adverse drug experiences (ADEs), grades 3 and 4, in antineoplastons study (ITT) compared to selected studies with temozolomide for pediatric brain tumors.

ADE (Incidence %)	Antineoplastons		Lashford <i>et al.</i> , 2002, Temozolomide [21]	Warren <i>et al.</i> , 2012, 06-Benzylguanine and Temozolomide [23]	
	Gr. 3	Gr. 4		Gr. 3	Gr. 4
Hypokalemia		2.3			
Hypernatremia	4.6	13.9			
Fatigue			1		
Somnolence	2.3	2.3			
Thrombocytopenia			7	17	2
Neutropenia				12	32
Leukopenia			5	15	10
Lymphopenia				24	2
Anemia				7	
Vomiting			2	2	
Anorexia			<1		
Infection				5	
Sepsis			2		
Pneumonia			2		
Fever					
Neuropathy			<1		
Seizures			<1		
Headache				2	
Pain			<1		

10. Conclusion

The treatment of recurrent primary malignant pediatric brain tumors creates great challenge for neuro-oncologists. This Phase II study of Antineoplastons A10 and AS2-1 reported encouraging responses and survival data in the heavily pretreated and refractory patient population. Of special interest are the results in recurrent DIPG and AA. The study reached the goal of four or more cases of OR in the ITT population. The data acquired in patients with recurrent DIPG and AA present improved survival outcomes due to ANP therapy and tolerable toxicity. The additional Phase II studies of ANP in pediatric tumors and currently organized Phase III studies in newly-diagnosed DIPG will provide additional data.

Acknowledgements

The authors express their appreciation to the doctors involved in the care of the patients: Drs. Alejandro Marquis, Robert A. Weaver, Robert I. Lewy, Eva Kubove, Barbara Szymkowski, and Mohammad Khan. Preparation of the manuscript was provided by Carolyn Powers, Adam Golonski, and Jennifer Pineda.

Conflict of Interest

The clinical trial was sponsored by Burzynski Research Institute, Inc. The authors are employed by Burzynski Clinic. Dr. Stanislaw R. Burzynski and Dr. Gregory S. Burzynski are share holders in Burzynski Research Institute, Inc. Dr. Stanislaw R. Burzynski is President of Burzynski Research Institute, Inc., Dr. Tomasz Janicki is Vice President of Clinical Trials at Burzynski Research Institute, Inc., Dr. Gregory S. Burzynski is Vice President of Burzynski Clinic, and Dr. Sheldon Brookman is Director of Pharmaceutical Development at Burzynski Clinic.

References

- [1] Porter, K.R., McCarthy, B.J., Freels, S., et al. (2010) Prevalence Estimates for Primary Brain Tumors in the United States by Age, Gender, Behavior and Histology. *Neuro-Oncology*, **12**, 520-527. <http://dx.doi.org/10.1093/neuonc/nop066>
- [2] CBTRUS (2013) CBTRUS Statistical Report Supplement 2013: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2006-2010. *Neuro-Oncology*, **15**, ii1-ii56.
- [3] Broniscer, A. and Gajjar, A. (2004) Supratentorial High-Grade Astrocytoma and Diffuse Brainstem Glioma: Two Challenges for the Pediatric Oncologist. *Oncologist*, **9**, 197-206. <http://dx.doi.org/10.1634/theoncologist.9-2-197>
- [4] Stupp, R., Mason, W.P., van den Bent, M.J., Weller, M., Fisher, B., et al. (2005) Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma. *The New England Journal of Medicine*, **352**, 987-996. <http://dx.doi.org/10.1056/NEJMoa043330>
- [5] Wick, W., Weller, M., Weiler, M., Batchelor, T., Yung, A.W. and Platten, M. (2011) Pathway Inhibition: Emerging Molecular Targets for Treating Glioblastoma. *Neuro-Oncology*, **13**, 566-579. <http://dx.doi.org/10.1093/neuonc/nor039>
- [6] Hargrave, D., Bartels, U. and Bouffet, E. (2006) Diffuse Brainstem Glioma in Children: Critical Review of Clinical Trials. *Lancet*, **7**, 241-248.
- [7] Finlay, J.L. and Zacharoulis, S. (2005) The Treatment of High Grade Gliomas and Diffuse Intrinsic Pontine Tumors of Childhood and Adolescence: A Historical and Futuristic Perspective. *Journal of Neuro-Oncology*, **75**, 253-266. <http://dx.doi.org/10.1007/s11060-005-6747-7>
- [8] Burzynski, S.R. (2004) The Present State of Antineoplaston Research (1). *Integrative Cancer Therapies*, **3**, 47-58. <http://dx.doi.org/10.1177/1534735403261964>
- [9] Burzynski, S.R. (2006) Treatments for Astrocytic Tumors in Children: Current and Emerging Strategies. *Pediatric Drugs*, **8**, 167-168. <http://dx.doi.org/10.2165/00148581-200608030-00003>
- [10] Burzynski, S.R., Janicki, T.J., Burzynski, G.S. and Marszalek, A. (2014) The Response and Survival of Children with Recurrent Diffuse Intrinsic Pontine Gliomas Based on Phase II Study of Antineoplastons A10 and AS2-1 in Patients with Brainstem Glioma. *Child's Nervous System*, Published Online.
- [11] Burzynski, S.R., Janicki, T.J., Burzynski, G.S. and Marszalek, A. (2014) Long-Term Survival (>13 Years) in a Child with Recurrent Diffuse Intrinsic Pontine Glioma: A Case Report. *Journal of Pediatric Hematology/Oncology*, Published Online.
- [12] Burzynski, S.R., Janicki, T.J., Burzynski, G.S. and Marszalek, A. (2014) A Phase II Study of Antineoplastons A10 and AS2-1 in Children with High-Grade Glioma. Final Report (Protocol BT-06), and Review of Recent Trials. *Journal of Cancer Therapy*, **5**, 565-577. <http://dx.doi.org/10.4236/jct.2014.56065>
- [13] Packer, R.J., Boyett, J.M., Zimmerman, R.A., Rorke, L.B., Kaplan, A.M., Albright, A.L., et al. (1993) Hyperfractionated Radiation Therapy (72 Gy) for Children with Brain Stem Gliomas. A Childrens Cancer Group Phase I/II Trial. *Cancer*, **72**, 1414-1421.
- [14] Albright, A.L., Packer, R.J., Zimmerman, R., Rorke, L.B., Boyett, J. and Hammond, G.D. (1993) Magnetic Resonance Scans Should Replace Biopsies for the Diagnosis of Diffuse Brain Stem Gliomas: A Report from the Children's Cancer Group. *Neurosurgery*, **33**, 1026-1030. <http://dx.doi.org/10.1227/00006123-199312000-00010>
- [15] Wen, P.Y., Macdonald, D.R., Reardon, D.A., Cloughesy, T.F., Sorensen, A.G., Galanis, E., et al. (2010) Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group. *Journal of Clinical Oncology*, **28**, 1963-1972. <http://dx.doi.org/10.1200/JCO.2009.26.3541>
- [16] Choux, M., Lena, G. and Do, L. (2000) Brainstem Tumors. In: Choux, M., Di Rocco, C. and Hockley, A., Eds., *Pediatric Neurosurgery*, Churchill Livingstone, New York, 471-491.
- [17] Leach, P.A., Estlin, E.J., Coope, D.J., Thorne, J.A. and Kamaly-Asl, I.D. (2008) Diffuse Brainstem Gliomas in Children: Should We or Shouldn't We Biopsy? *British Journal of Neurosurgery*, **22**, 619-625. <http://dx.doi.org/10.1080/02688690802366198>

- [18] Chang, S.M., Kuhn, J.G., Robins, H.I., Schold, S.C., Spence, A.M., Berger, M.S., *et al.* (1999) Phase II Study of Phenylacetate in Patients with Recurrent Malignant Glioma: A North American Brain Tumor Consortium Report. *Journal of Clinical Oncology*, **17**, 984-990.
- [19] Weller, M., Cloughesy, T., Perry, J.R. and Wisk, W. (2013) Standards of Care for Treatment of Recurrent Glioblastoma—Are We There Yet? *Neuro-Oncology*, **15**, 4-27. <http://dx.doi.org/10.1093/neuonc/nos273>
- [20] Van Meir, E.G., Hadjipanayis, C.G., Norden, A.D., Shu, H.K., Wen, P.Y. and Olson, J.J. (2010) Exciting New Advances in Neuro-Oncology: The Avenue to a Cure for Malignant Glioma. *CA: A Cancer Journal for Clinicians*, **60**, 166-193. <http://dx.doi.org/10.3322/caac.20069>
- [21] Lashford, L.S., Thiesse, P., Jouvett, A., Jaspan, T., Couanet, D., Griffiths, P.D., *et al.* (2002) Temozolomide in Malignant Gliomas of Childhood: A United Kingdom Children's Cancer Study Group and French Society for Pediatric Oncology Intergroup Study. *Journal of Clinical Oncology*, **20**, 4684-4691. <http://dx.doi.org/10.1200/JCO.2002.08.141>
- [22] Nicholson, H.S., Kretschmar, C.S., Krailo, M., Bernstein, M., Kadota, R., Fort, D., *et al.* (2007) Phase 2 Study of Temozolomide in Children and Adolescents with Recurrent Central Nervous System Tumors. A Report from the Children's Oncology Group. *Cancer*, **110**, 1542-1550. <http://dx.doi.org/10.1002/cncr.22961>
- [23] Warren, K.E., Gururangan, S., Geyer, J.R., McLendon, R.E., Poussaint, T.Y., Wallace, D., *et al.* (2012) A Phase II Study of 06-Benzylguanidine and Temozolomide in Pediatric Patients with Recurrent or Progressive High-Grade Gliomas and Brainstem Gliomas: A Pediatric Brain Tumor Consortium Study. *Journal of Neuro-Oncology*, **106**, 643-649. <http://dx.doi.org/10.1007/s11060-011-0709-z>